172 related articles for article (PubMed ID: 23732280)
1. Therapy: Immunotherapy for T1DM--targeting innate immunity.
Wong FS; Wen L
Nat Rev Endocrinol; 2013 Jul; 9(7):384-5. PubMed ID: 23732280
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulators: Cell savers.
DeWeerdt S
Nature; 2012 May; 485(7398):S4-5. PubMed ID: 22616095
[No Abstract] [Full Text] [Related]
3. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation.
Ablamunits V; Henegariu O; Hansen JB; Opare-Addo L; Preston-Hurlburt P; Santamaria P; Mandrup-Poulsen T; Herold KC
Diabetes; 2012 Jan; 61(1):145-54. PubMed ID: 22043003
[TBL] [Abstract][Full Text] [Related]
4. Targeting innate immunity in type 1 diabetes: strike one.
Bonifacio E
Lancet; 2013 Jun; 381(9881):1880-1. PubMed ID: 23562091
[No Abstract] [Full Text] [Related]
5. Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.
Cabrera SM; Wang X; Chen YG; Jia S; Kaldunski ML; Greenbaum CJ; ; Mandrup-Poulsen T; ; Hessner MJ
Eur J Immunol; 2016 Apr; 46(4):1030-46. PubMed ID: 26692253
[TBL] [Abstract][Full Text] [Related]
6. Anti-cytokine therapies in T1D: Concepts and strategies.
Nepom GT; Ehlers M; Mandrup-Poulsen T
Clin Immunol; 2013 Dec; 149(3):279-85. PubMed ID: 23510726
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Type 1 diabetes: getting beyond a negative first impression.
Pozzilli P; Strollo R
Immunotherapy; 2012 Jul; 4(7):655-8. PubMed ID: 22853748
[No Abstract] [Full Text] [Related]
8. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.
Woerner A; von Scheven-Gête A; Cimaz R; Hofer M
Expert Rev Clin Immunol; 2015 May; 11(5):575-88. PubMed ID: 25843554
[TBL] [Abstract][Full Text] [Related]
9. Human Vaccines & Immunotherapeutics: News.
Hum Vaccin Immunother; 2018 Jan; 14(1):9-10. PubMed ID: 29324172
[No Abstract] [Full Text] [Related]
10. Targeting innate immunity for treatment of type 1 diabetes.
Bednar KJ; Ridgway WM
Immunotherapy; 2014; 6(12):1239-42. PubMed ID: 25524380
[No Abstract] [Full Text] [Related]
11. The anti-interleukin-1 in type 1 diabetes action trial--background and rationale.
Pickersgill LM; Mandrup-Poulsen TR
Diabetes Metab Res Rev; 2009 May; 25(4):321-4. PubMed ID: 19405081
[TBL] [Abstract][Full Text] [Related]
12. Immunospecific therapy for type I diabetes mellitus.
Culler FL; O'Connor R; Kaufmann S; Jones KL; Roth JC
N Engl J Med; 1985 Sep; 313(11):695-6. PubMed ID: 3875034
[No Abstract] [Full Text] [Related]
13. Diabetes: type 1 diabetes mellitus--a door opening to a real therapy?
Chatenoud L
Nat Rev Endocrinol; 2011 Aug; 7(10):564-6. PubMed ID: 21878898
[No Abstract] [Full Text] [Related]
14. Modulation of virus-induced innate immunity and type 1 diabetes by IL-1 blockade.
Hara N; Alkanani AK; Dinarello CA; Zipris D
Innate Immun; 2014 Aug; 20(6):574-84. PubMed ID: 24062197
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.
Guglielmi C; Williams SR; Del Toro R; Pozzilli P
Expert Opin Biol Ther; 2016 Jun; 16(6):841-6. PubMed ID: 27145230
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapies in diabetes mellitus type 1.
Gupta S
Med Clin North Am; 2012 May; 96(3):621-34, xi. PubMed ID: 22703858
[TBL] [Abstract][Full Text] [Related]
17. Preservation of beta cell function.
Sperling MA
Pediatr Diabetes; 2010 May; 11(3):152-3. PubMed ID: 20546532
[No Abstract] [Full Text] [Related]
18. [New treatments for rheumatoid arthritis].
Girault V; Flipo RM
Soins; 2004 Sep; (688):37-8. PubMed ID: 15515847
[No Abstract] [Full Text] [Related]
19. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis.
Volarevic V; Al-Qahtani A; Arsenijevic N; Pajovic S; Lukic ML
Autoimmunity; 2010 Jun; 43(4):255-63. PubMed ID: 19845478
[TBL] [Abstract][Full Text] [Related]
20. Treatment of adult-onset still's disease: up to date.
Yoo DH
Expert Rev Clin Immunol; 2017 Sep; 13(9):849-866. PubMed ID: 28540751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
